Vergoeding 2020-2024 voor ATC-subgroep R03DX : Overige middelen bij astma/copd voor systemisch gebruik
- Raming voor de totale Zvw-populatie
| 2020 | 2021 | 2022 | 2023* | 2024* | |
|---|---|---|---|---|---|
| R03DX05 Omalizumab | 37.814.820 | 35.523.918 | 36.237.560 | 39.441.701 | 34.957.945 |
| R03DX08 Reslizumab | 3.032.737 | 2.729.678 | 2.385.567 | 2.206.955 | 1.714.605 |
| R03DX09 Mepolizumab | 18.889.323 | 18.570.201 | 19.479.397 | 23.151.427 | 23.958.866 |
| R03DX10 Benralizumab | 12.246.371 | 13.861.906 | 16.148.818 | 17.220.080 | 14.398.869 |
| R03DX11 Tezepelumab | . | . | . | 45.763 | 743.852 |
| Totaal | 71.983.252 | 70.685.703 | 74.251.342 | 82.065.926 | 75.774.138 |